Mizuho Lowers Price Target for Boston Scientific Ahead of Q1 Earnings
Mizuho Financial lowered its price target for Boston Scientific Corporation (BSX) from $115 to $90, maintaining an Outperform rating ahead of the company's first-quarter earnings. The adjustment is part of a broader review of medical devices and diagnostics coverage. Additionally, Boston Scientific and Penumbra, Inc. received a Second Request from the FTC regarding their merger, extending the regulatory review timeline.
Topics: analyst rating medical devices merger regulatory review stock price target